154 results on '"Porte, Robert J."'
Search Results
2. Viability assessment of the liver during ex-situ machine perfusion prior to transplantation.
3. Continuous Renal Replacement Therapy During Long-term Normothermic Machine Perfusion of Human Donor Livers for up to 7 D.
4. Novel Benchmark Values for Redo Liver Transplantation. Does the Outcome Justify the Effort?
5. Waitlist mortality of young patients with biliary atresia: Impact of allocation policy and living donor liver transplantation.
6. Liver Transplantation as a New Standard of Care in Patients With Perihilar Cholangiocarcinoma? Results From an International Benchmark Study.
7. Delivering siRNA Compounds During HOPE to Modulate Organ Function: A Proof-of-concept Study in a Rat Liver Transplant Model.
8. The Emerging Role of Viability Testing During Liver Machine Perfusion.
9. Nonmalignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin‐rich thrombus.
10. Persistent biliary hypoxia and lack of regeneration are key mechanisms in the pathogenesis of posttransplant nonanastomotic strictures.
11. Bile Composition as a Diagnostic and Prognostic Tool in Liver Transplantation.
12. Transplantation of High-risk Donor Livers After Ex Situ Resuscitation and Assessment Using Combined Hypo- and Normothermic Machine Perfusion: A Prospective Clinical Trial.
13. Biliary Bicarbonate, pH, and Glucose Are Suitable Biomarkers of Biliary Viability During Ex Situ Normothermic Machine Perfusion of Human Donor Livers.
14. Peribiliary Glands Are Key in Regeneration of the Human Biliary Epithelium After Severe Bile Duct Injury.
15. Plasma From Patients Undergoing Liver Transplantation Is Resistant to Anticoagulant Activity of Soluble Thrombomodulin.
16. Elevated Plasma Levels of Cell‐Free DNA During Liver Transplantation Are Associated With Activation of Coagulation.
17. Production of Physiologically Relevant Quantities of Hemostatic Proteins During Ex Situ Normothermic Machine Perfusion of Human Livers.
18. Hypothermic oxygenated machine perfusion reduces bile duct reperfusion injury after transplantation of donation after circulatory death livers.
19. Normothermic machine perfusion of donor livers without the need for human blood products.
20. Trajectories of Anxiety and Depression After Liver Transplantation as Related to Outcomes During 2-Year Follow-Up: A Prospective Cohort Study.
21. Peritransplant Energy Changes and Their Correlation to Outcome After Human Liver Transplantation.
22. Liver ex situ machine perfusion preservation: A review of the methodology and results of large animal studies and clinical trials.
23. Value of Preoperative Hemostasis Testing in Patients with Liver Disease for Perioperative Hemostatic Management.
24. Activation of Fibrinolysis, But Not Coagulation, During End-Ischemic Ex Situ Normothermic Machine Perfusion of Human Donor Livers.
25. Multifactorial biological modulation of warm ischemia reperfusion injury in liver transplantation from non-heart-beating donors eliminates primary nonfunction and reduces bile salt toxicity
26. Longterm results of liver transplantation from donation after circulatory death.
27. Normothermic machine perfusion reduces bile duct injury and improves biliary epithelial function in rat donor livers.
28. Oxygenated Hypothermic Machine Perfusion After Static Cold Storage Improves Hepatobiliary Function of Extended Criteria Donor Livers.
29. Viability Criteria for Functional Assessment of Donor Livers During Normothermic Machine Perfusion.
30. End-ischemic machine perfusion reduces bile duct injury in donation after circulatory death rat donor livers independent of the machine perfusion temperature.
31. Opinions of Dutch Liver Transplant Recipients on Anonymity of Organ Donation and Direct Contact With the Donors Family.
32. Prevalence of psychological problems and associated transplant-related variables at different time periods after liver transplantation.
33. Shared decision making in transplantation: How patients see their role in the decision process of accepting a donor liver.
34. Biliary complications after orthotopic liver transplantation.
35. Duct-to-duct reconstruction in liver transplantation for primary sclerosing cholangitis is associated with fewer biliary complications in comparison with hepaticojejunostomy.
36. An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: Implications for hemostasis and clinical outcome.
37. Hepatic Hemangiosarcoma.
38. Management of Nonneoplastic Portal Vein Thrombosis in the Setting of Liver Transplantation.
39. Validation of the donor risk index in orthotopic liver transplantation within the Eurotransplant region.
40. Place of liver transplantation in the treatment of hepatocellular carcinoma in the normal liver.
41. Prothrombotic Gene Polymorphisms: Possible Contributors to Hepatic Artery Thrombosis After Orthotopic Liver Transplantation.
42. Protection of Bile Ducts in Liver Transplantation: Looking Beyond Ischemia.
43. Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9.
44. Lectin complement pathway gene profile of donor and recipient determine the risk of bacterial infections after orthotopic liver transplantation.
45. Long-term results of urgent revascularization for hepatic artery thrombosis after pediatric liver transplantation.
46. Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha-2b.
47. Multifactorial Biological Modulation of Warm Ischemia Reperfusion Injury in Liver Transplantation From Non-Heart-Beating Donors Eliminates Primary Nonfunction and Reduces Bile Salt Toxicity.
48. Prevalence of hepatitis E virus infection in liver transplant recipients.
49. The clinical relevance of the anhepatic phase during liver transplantation.
50. No evidence for systemic platelet activation during or after orthotopic liver transplantation.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.